Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glpg-0259. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 known ✓ | Q8IW41 | 11/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glpg-0259 SCHEMBL1570157 | 1.00 | MAPKAPK5 (0.49) | MAPKAPK5SYKTTKMAP3K12BTK | |
| Glpg-0259 SCHEMBL12661679 | 1.00 | MAPKAPK5 (0.49) | MAPKAPK5SYKTTKMAP3K12BTK | |
| SCHEMBL1570061 | 0.94 | MAPKAPK5 (0.49) | MAPKAPK5SYKTTKBTK | |
| SCHEMBL1570224 | 0.92 | MAPKAPK5 (0.42) | MAPKAPK5SYKTTKMAP3K12 | |
| SCHEMBL2389923 | 0.91 | MAPKAPK5 (0.42) | MAPKAPK5SYKTTKMAP3K12BTK | |
| SCHEMBL2390918 | 0.89 | MAPKAPK5 (0.48) | MAPKAPK5SYKBTK | |
| SCHEMBL2390549 | 0.89 | MAPKAPK5 (0.48) | MAPKAPK5SYKBTK | |
| SCHEMBL2389877 | 0.87 | MAPKAPK5 (0.64) | MAPKAPK5SYKTTK | |
| SCHEMBL1570213 | 0.84 | MAPKAPK5 (0.49) | MAPKAPK5SYKTTK | |
| SCHEMBL1570149 | 0.84 | MAPKAPK5 (0.53) | MAPKAPK5SYKTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2011-05-19 | — | — | US | disclosed |
| WO-2011054922-A1 | SALTS OF FUSED PYRAZINE COMPOUNDS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2011-05-12 | — | — | WO | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| WO-2009135885-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, NLRP3 | MAPKAPK5 89/4885SYK 2268/4885TTK 3511/4885 |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, PTGER1 | MAPKAPK5 131/4885SYK 3339/4885TTK 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.